Aprepitant Not Superior to Metoclopramide in Preventing Cisplatin-Induced Emesis

Share this content:
Aprepitant plus dexamethasone is not superior in preventing delayed emesis in patients with cancer receiving cisplatin-based chemotherapy
Aprepitant plus dexamethasone is not superior in preventing delayed emesis in patients with cancer receiving cisplatin-based chemotherapy

According to a new study published online in the journal Annals of Oncology, researchers have found that aprepitant plus dexamethasone is not superior to metoclopramide plus dexamethasone in preventing delayed emesis in patients with cancer receiving cisplatin-based chemotherapy

For the double-blind study, researchers sought to determine if aprepitant, a 5-HT3 receptor antagonist, in combination with dexamethasone is superior to metoclopramide plus dexamethasone in preventing delayed emesis in patients with cancer receiving the same antiemetic prophylaxis for acute emesis.

Researchers randomly assigned patients to receive dexamethasone 8mg PO on days 2-4 plus aprepitant 80mg once daily on days 2-3 or metoclopramide 20mg four times daily plus dexamethasone 8mg two times daily.

RELATED: Weekly Docetaxel Plus Cisplatin Not Superior to Docetaxel Monotherapy in Elderly Lung Cancer

All patients were treated with palonosetron 0.25mg, dexamethasone 12mg, and aprepitant 125mg before chemotherapy.

Results showed that there was no significant difference in complete response rates on day 2-5 (80.3% with aprepitant vs 82.5% with metoclopramide; P < 0.38).

Complete protection, total control, no nausea, no vomiting, and score of Functional Living Index-Emesis were also similar in both arms (P < 0.24). In regard to toxicity, no significant difference in adverse events incidence was observed.

Reference

  1. Roila F, Ruggeri B, Ballatori E, et al. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv132.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters